Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009
- PMID: 20589368
- DOI: 10.1007/s00198-010-1335-x
Efficacy, side effects and route of administration are more important than frequency of dosing of anti-osteoporosis treatments in determining patient adherence: a critical review of published articles from 1970 to 2009
Abstract
The purposes of the study were to review available published literature on magnitude of non-adherence with osteoporosis regimens and to determine the association between frequency and modality of medication administration with patient preference and adherence. We searched peer-reviewed journal databases--MEDLINE, EMBASE, Biosis and Derwent Drug File for publications (January 1979 to January 2009) including MeSH terms--"patient preference", "adherence" and "compliance" based on "dosing frequency" and "modality". Since adherence was difficult to accurately quantify, preference, compliance and persistence were evaluated. Patients' preference and adherence at 12 months were higher with weekly over daily bisphosphonates (≥ 84% preference for weekly, medication possession ratios (MPR) 60-76% vs 46-64%; persistence 43.6-69.7% vs 31.7-55.7%). MPR reported for oral bisphosphonates were 68-71% at 12 months. At 2 years, only 43% of patients had MPR ≥ 80% for daily and weekly bisphosphonates. Observational studies (6-12 months) reported discontinuation rates of 18-22% for daily and 7% for weekly bisphosphonates. Data on monthly bisphosphonates are conflicting and confounded by cost differences, patient support programmes and definition of persistence. Studies suggest patient preference for annual zoledronic acid infusions over weekly bisphosphonates (66.4-78.8% vs 9.0-19.7%, respectively), but no data on compliance or persistence are available. Drug effectiveness, side effects and route of administration were more important than frequency. Although less frequent dosing is preferred, other factors such as perceived efficacy, side effects, medication cost, availability of patient support programmes and route of delivery are equally important. Adherence is complex and difficult to quantify and may not be exclusively influenced by frequency of medication administration.
Similar articles
-
Two-year persistence and compliance with osteoporosis therapies among postmenopausal women in a commercially insured population in the United States.Arch Osteoporos. 2017 Dec;12(1):22. doi: 10.1007/s11657-017-0316-5. Epub 2017 Feb 28. Arch Osteoporos. 2017. PMID: 28243883 Free PMC article.
-
Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis.Curr Med Res Opin. 2005 Sep;21(9):1453-60. doi: 10.1185/030079905X61875. Curr Med Res Opin. 2005. PMID: 16197664
-
Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.Treat Endocrinol. 2005;4(4):245-51. doi: 10.2165/00024677-200504040-00005. Treat Endocrinol. 2005. PMID: 16053341 Review.
-
Adherence to osteoporosis medications amongst Singaporean patients.Osteoporos Int. 2012 Mar;23(3):1053-60. doi: 10.1007/s00198-011-1635-9. Epub 2011 Apr 19. Osteoporos Int. 2012. PMID: 21503813
-
Bisphosphonate alternative regimens for the prevention of osteoporotic fragility fractures: BLAST-OFF, a mixed-methods study.Health Technol Assess. 2024 Apr;28(21):1-169. doi: 10.3310/WYPF0472. Health Technol Assess. 2024. PMID: 38634483 Free PMC article.
Cited by
-
Osteoporosis: a discussion on the past 5 years.Curr Rev Musculoskelet Med. 2017 Jun;10(2):265-274. doi: 10.1007/s12178-017-9410-y. Curr Rev Musculoskelet Med. 2017. PMID: 28389970 Free PMC article. Review.
-
Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate.Osteoporos Int. 2014 Jul;25(7):1953-61. doi: 10.1007/s00198-014-2692-7. Epub 2014 Mar 28. Osteoporos Int. 2014. PMID: 24676847
-
Adherence and preference of intravenous zoledronic acid for osteoporosis versus other bisphosphonates.Eur J Hosp Pharm. 2019 Jan;26(1):4-9. doi: 10.1136/ejhpharm-2017-001258. Epub 2017 Sep 20. Eur J Hosp Pharm. 2019. PMID: 31157088 Free PMC article. Review.
-
Long-term persistence and switching patterns among women using osteoporosis therapies: 24- and 36-month results from POSSIBLE US™.Osteoporos Int. 2014 Sep;25(9):2279-90. doi: 10.1007/s00198-014-2762-x. Epub 2014 Jun 19. Osteoporos Int. 2014. PMID: 24942502
-
Nominal group technique to select attributes for discrete choice experiments: an example for drug treatment choice in osteoporosis.Patient Prefer Adherence. 2013;7:133-9. doi: 10.2147/PPA.S38408. Epub 2013 Feb 7. Patient Prefer Adherence. 2013. PMID: 23412964 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources